Publications
375
Citations
9,707
Est. group size
~35
Recurring co-author estimate
Active years
29
Publishing since 1998
Typically publishes in teams of ~9 · 13% small-team papers (≤3 authors) · across 20 venues
- Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer
JCO Oncology Practice · 2025
- USING RE-AIM TO IDENTIFY IMPLEMENTATION DETERMINANTS OF CARDIOVASCULAR RISK STRATIFICATION SCORE FOR PATIENTS WITH PROSTATE CANCER
medRxiv · 2025
- Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer
Clinical Genitourinary Cancer · 2024
- Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)
European Journal of Cancer · 2022
- Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients
Cells · 2022
- MP48-05 CHANGES IN PITUITARY–GONADAL HORMONES AFTER ENZALUTAMIDE OR ABIRATERONE PLUS PREDNISONE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER (HEAT): RESULTS FROM A RANDOMISED CLINICAL TRIAL
The Journal of Urology · 2022
- Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
Prostate Cancer and Prostatic Diseases · 2021
- Glypican‐1 as a target for fluorescence molecular imaging of bladder cancer
International Journal of Urology · 2021
- PD34-06 SERUM TESTOSTERONE AS A PREDICTIVE BIOMARKER FOR PSA RESPONSE: RESULTS FROM A RANDOMISED TRIAL COMPARING ENZALUTAMIDE WITH ABIRATERONE ACETATE PLUS PREDNISONE
The Journal of Urology · 2021
- COVID and CopMich: comparing and contrasting COVID-19 experiences in the USA and Scandinavia
Nature Reviews Urology · 2020
- Methionine-Homocysteine Pathway in African-American Prostate Cancer
JNCI Cancer Spectrum · 2019
- TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
PLoS ONE · 2019
- Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
Kidney Cancer · 2019
- Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
BMJ Open · 2019
- TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2019
- The Journal of Urology×46
- Journal of Clinical Oncology×21
- Urology×8
- Urologic Oncology Seminars and Original Investigations×6
- International Journal of Radiation Oncology*Biology*Physics×6
- Todd M. Morgan
Medicine · University of Michigan
- Simpa S. Salami
Medicine · University of Michigan
- Suguru Kadomoto
Medicine · University of Michigan
- Stephanie Daignault
Medicine · University of Michigan
- Lakshmi P. Kunju
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile